1 completed, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow KRAS G12C Mutation: new trials by email Literature Review of KRAS G12C Mutation trials Research Report on KRAS G12C Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB365, Cetuximab, KQB198 - KRAS G12C Mutation, KRAS G12S Mutation | Phase 1 | Recruiting | Kumquat Biosciences Inc. | 140 | 2025-02-04 | 2026-11-03 |
| Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation BEBT-607Tablets - Advanced or Metastatic Solid Tumor, KRAS G12C Mutation | Phase 1 | Completed | BeBetter Med Inc | 11 | 2023-09-18 | 2026-08-18 |
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1)
Cetuximab (1)
BeBetter Med Inc (1) · Kumquat Biosciences Inc. (1)
China (1) · United States (1)
Heli Liu, Ph.D (1)